Moderna touts 'superior' antibody levels against Omicron for authorized Covid-19 bivalent booster

In September, Moderna received FDA emergency use authorization for its BA.4/BA.5-targeting bivalent booster vaccine, mRNA-1273.222, based on preclinical data for the shot as well as Phase II/III clinical trial data studying a similar bivalent booster targeting the Omicron BA.1 subvariant.